Search

A 20-year-old pregnant woman with late-diagnosed atrial septal defect and pulmonary arterial hypertension (PAH) exhibited lack of efficacy during treatment with bosentan. After starting iloprost inhalation therapy, she showed functional improvement, but her pregnancy was terminated due to fetal distress. Following surgery, she resumed bosentan treatment for PAH, but unfortunately experienced severe hypoxia leading to cardiorespiratory arrest and ultimately passed away, indicating lack of efficacy to bosentan therapy. [Extracted from the article]

A 29-year-old woman experienced a lack of efficacy while being treated with heparin and rivaroxaban for pulmonary embolism. Despite a history of recurrent pulmonary emboli and various medical conditions, she initially declined anti-coagulation during a brief period, leading to worsening symptoms. Subsequent treatment with heparin and rivaroxaban proved ineffective, requiring a switch to warfarin for stabilization. [Extracted from the article]

A 70-year-old man experienced hypotension while being treated with nitroglycerin for chest pain related to coronary artery disease. Despite receiving nitroglycerin infusion, he developed hypotension, leading to various complications such as acute kidney injury, cardiogenic shock, and liver injury. The man's treatment included intra-aortic balloon pump placement, and he underwent procedures like extra corporeal membrane oxygenation and Impella RP flex to address his deteriorating condition. The outcome of the adverse drug reaction was not specified in the report. [Extracted from the article]

Three case reports were described involving patients aged 63-67 who experienced toxicities and lack of efficacy while being treated for various types of cancer. The patients developed hepatitis, myocarditis, hand-foot syndrome, maculopapular skin rash, or rhabdomyolysis during treatment with drugs such as nivolumab, sorafenib, and pembrolizumab. In one case, a patient experienced hepatitis and myocarditis after receiving nivolumab, but showed improvement after treatment with methylprednisolone. Another patient developed myocarditis and rhabdomyolysis after receiving pembrolizumab and ultimately passed away due to cardiogenic shock and multiple organ failure. These case reports highlight the potential toxicities and lack of efficacy associated with certain cancer treatments. [Extracted from the article]

A 58-year-old woman experienced euglycemic diabetic ketoacidosis while being treated with ertugliflozin for type 2 diabetes. The woman had a medical history of chronic hypersensitivity pneumonitis, hypertension, asthma, and gastroesophageal reflux disease. She was also listed for lung transplantation. After undergoing surgery, she developed an anion gap metabolic acidosis and elevated serum lactate. Further investigation revealed that the euglycemic diabetic ketoacidosis was caused by ertugliflozin. The patient required insulin and glucose supplementation to manage the condition. She experienced complications during her hospital stay but eventually recovered and was discharged. [Extracted from the article]

A 30-year-old woman with fanconi anemia developed ectopic atrial bradycardia and fever during treatment with fludarabine and antithymocyte-globulin. She had a history of type 2 diabetes and immigrated from the Dominican Republic with a long-standing history of anemia and thrombocytopenia. The woman received a haploidentical cell transplant and chemotherapy, including antithymocyte-globulin and fludarabine. She experienced bradycardia and fever during treatment, but her symptoms improved with steroids and her heart rate returned to baseline after completing the fludarabine infusions. Follow-up tests showed normal heart function. [Extracted from the article]

A 14-year-old boy experienced lack of efficacy during treatment with adenosine and sodium-chloride for supraventricular tachycardia. His condition presented with various symptoms, including weight loss, hypotension, and tachycardia, leading to a critical state. Despite treatment, his supraventricular tachycardia did not resolve, and he required intensive care, including intubation and ventilation. Ultimately, he was discharged with a diagnosis of new onset type 1 diabetes and mixed hyperglycemic hyperosmolar syndrome and diabetic ketoacidosis. [Extracted from the article]

A 46-year-old woman with pulmonary arterial hypertension (PAH) experienced a lack of efficacy during treatment with multiple drugs, including epoprostenol, macitentan, nitric-oxide, tadalafil, and treprostinil. Despite changes in therapy and receiving epoprostenol and nitric-oxide, she progressed to right ventricular failure and shock. She underwent a lung transplant evaluation and received venoarterial extracorporeal membrane oxygenation (VA-ECMO) as a bridge to transplant. However, she developed complications and ultimately died from acute severe cardiogenic shock with multi-system organ failure. The lack of efficacy of treprostinil, tadalafil, and macitentan was considered in her case. [Extracted from the article]

An 85-year-old man with a history of chronic obstructive pulmonary disease and hypertension was treated with cyclophosphamide, prednisone, and rituximab for primary cardiac lymphoma (PCL) and diffuse large B-cell lymphoma (DLBCL). However, he exhibited a lack of efficacy and was readmitted to the hospital for primary right heart failure and transient third-degree heart block. Despite treatment, his condition worsened, and he ultimately died from PCL 4.5 months after his initial symptoms appeared. [Extracted from the article]

A 45-year-old woman experienced acute right heart failure and acute right ventricular dysfunction while being treated with entrectinib for stage IV lung adenocarcinoma with brain metastases. After four days of starting entrectinib, she developed marked fatigue, hypotension, and ST segment elevation on an ECG. Coronary angiography showed no evidence of coronary disease, and further evaluation indicated acute right heart failure. The patient received supportive therapy and her condition improved, leading to the conclusion that the acute right ventricular dysfunction and subsequent heart failure were caused by entrectinib. [Extracted from the article]

In a retrospective cohort study, two adult patients developed cardiac toxicity while receiving treatment with cyclophosphamide for unspecified indications. The first patient experienced global myocarditis involving both left and right ventricular dysfunction and was admitted to the ICU. The second patient showed pathological evidence of hypersensitivity myocarditis and was also admitted to the ICU. Both cases were diagnosed with cardiac toxicity secondary to cyclophosphamide based on clinical presentation. [Extracted from the article]

A 36-year-old woman with hypothyroidism and systemic sclerosis exhibited lack of efficacy during treatment with clindamycin, doxycycline, and azithromycin. She presented to the hospital with ventricular tachycardia and supraventricular tachycardia and was admitted. Despite receiving treatment, she developed cardiac manifestations of progressive systemic sclerosis, indicating lack of efficacy. She was started on mycophenolate as an immunosuppressive agent and discharged. On follow-up, she continued conservative management with homeopathic intervention and did not experience a recurrence of tachycardia. [Extracted from the article]

A 62-year-old man with heart failure and other medical conditions was treated with milrinone for heart failure and amiodarone and lidocaine for ventricular tachycardia. However, the patient did not respond well to the milrinone, and his condition worsened. He also developed ventricular tachycardia that did not respond to the amiodarone and lidocaine. After discussions with a multidisciplinary team, the patient underwent a successful procedure to treat the ventricular tachycardia. He was discharged from the hospital in stable condition one week later. [Extracted from the article]

A 26-year-old man experienced a submassive pulmonary embolism while being treated with testosterone for hypogonadism. He presented to the emergency department with sudden breathlessness and epigastric pain. Upon further investigation, it was determined that the pulmonary embolism was related to the testosterone therapy. The man underwent thrombolysis and showed good clinical improvement. He was discharged on dabigatran-etexilate tablets. [Extracted from the article]

A male neonate was treated for COVID-19 bronchiolitis with dexamethasone, nitric oxide, and unspecified catecholamines on an off-label basis. However, the treatment did not prove effective, and the patient's respiratory condition worsened. He developed pneumothorax and required invasive mechanical ventilation and inhalation of nitric oxide, but the hypoxemia did not improve. The patient also developed shock and received unspecified catecholamines, but the shock did not respond to the treatment. The neonate ultimately died from COVID-19 bronchiolitis, with additional complications including severe pulmonary hypertension, right ventricular dysfunction, patent ductus arteriosus, and acute kidney injury. [Extracted from the article]

She developed supra systemic pulmonary hypertension during pulmonary artery clamping test and dissection of both lungs. Further, she underwent peripheral vascular access placement along with monitoring of invasive arterial pressure and an epidural catheter was placed for management of pain post surgery. Postoperative Liver Failure Secondary to Hypoxic Hepatitis in Double Lung Transplantation: A Case Report. [Extracted from the article]

Amiodarone/procainamide: Lack of efficacy: 3 case reports However, post implantation, he continued to have recurring heart failure exacerbation with right ventricular dysfunction and atrial fibrillation, despite receiving treatment with amiodarone and unspecified beta blockade (lack of efficacy). Case 2 (A 50-year-old man): The man, who had ischaemic cardiomyopathy, permanent atrial fibrillation and chronic kidney disease, underwent HeartMate 3 implantation for refractory heart failure. [Extracted from the article]

Right heart catheterization (RHC) confirmed the diagnosis of severe precapillary PAH with pulmonary artery wedge pressure (PAWP) 5 mmHg, mean pulmonary arterial pressure (mPAP) 32 mmHg, cardiac index (CI) 1.8 L/min/m SP 2 sp and pulmonary vascular resistance (PVR) 8.5WU. She received treatment with first-line chemotherapy combining doxorubicin, vinblastine, bleomycin and dacarbazine, then an external radiotherapy treatment followed by a second line treatment combining dexamethasone, cisplatin and cytarabine and a third-line treatment combining doxorubicin, etoposide and ifosfamide. She received two lines of chemotherapy, including vincristine, ifosfamide, etoposide and doxorubicin as the first line treatment followed by vincristine, actinomycin A and ifosfamide as the second-line treatment. [Extracted from the article]

Acute respiratory failure and right ventricular dysfunction was secondary to pulmonary embolism. Pulmonary embolism with junctional tachycardia: A serious complication after COVID-19 vaccination. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 49-year-old man developed pulmonary embolism following vaccination with tozinameran against COVID-19 [ I route and dosage not stated; time to reaction onset not clearly stated i ]. [Extracted from the article]

She was noticed to have left leg swelling which on doppler ultrasound showed deep vein thrombosis (DVT). Despite being compliant with apixaban [Eliquis] for atrial fibrillation, she developed a DVT, indicating lack of efficacy to apixaban. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 72-year-old woman exhibited lack of efficacy during treatment with apixaban for atrial fibrillation [ I dosage and route not stated i ] The woman with atrial fibrillation, rheumatoid arthritis and pernicious anaemia came with 1 week of nausea, vomiting and abdominal pain. [Extracted from the article]

Due to the development of chemotherapy related febrile neutropenia at the first time, his treatment was modified to four weekly doses of vincristine at 50% dose and a single dose of dactinomycin. He received five doses of weekly injection of vincristine and one dose of injection dactinomycin [actinomycin-D]. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 2-year-old boy developed febrile neutropenia and hoarseness of voice during treatment with cyclophosphamide, dactinomycin and vincristine for stage-IV Wilms tumor [ I dosage not stated; not all duration of treatment to reaction onset and outcomes stated i ]. [Extracted from the article]